Presentation is loading. Please wait.

Presentation is loading. Please wait.

L. Julian Haywood, M. D. , Barry R. Davis, M. D. , Ph. D. , Linda B

Similar presentations


Presentation on theme: "L. Julian Haywood, M. D. , Barry R. Davis, M. D. , Ph. D. , Linda B"— Presentation transcript:

1 Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT 
L. Julian Haywood, M.D., Barry R. Davis, M.D., Ph.D., Linda B. Piller, M.D., M.P.H., William C. Cushman, M.D., Jeffrey A. Cutler, M.D., M.P.H., Charles E. Ford, Ph.D., Lara M. Simpson, Ph.D., Alokananda Ghosh, M.D., M.S., Elsayed Z. Soliman, M.D., M.Sc., M.S., Jackson T. Wright, M.D., Ph.D.  Journal of the National Medical Association  Volume 109, Issue 3, Pages (September 2017) DOI: /j.jnma Copyright © 2017 National Medical Association Terms and Conditions

2 Figure 1 Consort diagrams.
Journal of the National Medical Association  , DOI: ( /j.jnma ) Copyright © 2017 National Medical Association Terms and Conditions

3 Figure 2 Kaplan–Meier curves of cumulative incidence of all-cause mortality, cardiovascular death, and non-cardiovascular death for cases with baseline atrial fibrillation/atrial flutter or in-trial atrial fibrillation/atrial flutter, for all chlorthalidone, amlodipine, and lisinopril groups. Journal of the National Medical Association  , DOI: ( /j.jnma ) Copyright © 2017 National Medical Association Terms and Conditions

4 Figure 3 Kaplan–Meier curves of cumulative incidence of all cause-mortality, cardiovascular death, and non-cardiovascular death for cases with either baseline atrial fibrillation/atrial flutter or incident baseline atrial fibrillation/atrial flutter, for the pravastatin and usual care groups. Journal of the National Medical Association  , DOI: ( /j.jnma ) Copyright © 2017 National Medical Association Terms and Conditions


Download ppt "L. Julian Haywood, M. D. , Barry R. Davis, M. D. , Ph. D. , Linda B"

Similar presentations


Ads by Google